Clinical Trial Update: Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing INNO-206 to doxorubicin in advanced soft tissue sarcoma reports preliminary efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Doxorubicin (doxorubicin)
• INNO-206

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2024-05-29